apotex-amisulpride 400 mg tablet blister pack
gm pharma international pty ltd - amisulpride, quantity: 400 mg - tablet, film coated - excipient ingredients: titanium dioxide; sodium starch glycollate type a; methylcellulose; magnesium stearate; macrogol 6000; microcrystalline cellulose; lactose monohydrate; purified talc; basic butylated methacrylate copolymer - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
amisulpride 50 winthrop amisulpride 50 mg tablet blister pack
sanofi-aventis australia pty ltd - amisulpride -
amisulpride winthrop amisulpride 100mg/ml oral solution bottle
sanofi-aventis australia pty ltd - amisulpride -
solian 400 mg
sanofi israel ltd - amisulpride - film coated tablets - amisulpride 400 mg - amisulpride - amisulpride - treatment of schizophrenia.
solian tablet 400 mg
sanofi-aventis singapore pte. ltd. - amisulpride - tablet, film coated - 400 mg - amisulpride 400 mg
amisulpride scp amisulpride 400 mg uncoated tablet blister pack
southern cross pharma pty ltd - amisulpride, quantity: 400 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; sodium starch glycollate type a; microcrystalline cellulose; hypromellose - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
apotex-amisulpride 100 mg tablet blister pack
gm pharma international pty ltd - amisulpride, quantity: 100 mg - tablet - excipient ingredients: lactose monohydrate; sodium starch glycollate type a; magnesium stearate; methylcellulose; microcrystalline cellulose - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
apotex-amisulpride 200 mg tablet blister pack
gm pharma international pty ltd - amisulpride, quantity: 200 mg - tablet - excipient ingredients: sodium starch glycollate type a; microcrystalline cellulose; methylcellulose; magnesium stearate; lactose monohydrate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
apotex-amisulpride 50 mg tablet blister pack
gm pharma international pty ltd - amisulpride, quantity: 50 mg - tablet - excipient ingredients: microcrystalline cellulose; lactose monohydrate; sodium starch glycollate type a; methylcellulose; magnesium stearate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.
amisulpride scp amisulpride 50 mg uncoated tablet blister pack
southern cross pharma pty ltd - amisulpride, quantity: 50 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; lactose monohydrate; microcrystalline cellulose; magnesium stearate; hypromellose - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.